Gilead's Bictegravir Demonstrates Broad Non-Inferiority, But Will That Suffice?

30 May 2017

Having lost market share in recent years to HIV regimens containing ViiV's Tivicay, will a showing of non-inferiority across four head-to-head Phase III studies give bictegravir the market edge Gilead seeks?

Gilead Sciences Inc. revealed success demonstrating non-inferiority in four Phase III trials testing its investigational integrase inhibitor bictegravir head-to-head against other HIV therapy regimens, but it remains unclear whether these findings will give the virology specialist an edge against ViiV Healthcare's Tivicay (dolutegravir).

The Foster City, Calif.-based firm reported May 30 that bictegravir met the standard for non-inferiority in studies using comparator regimens...